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SUMMARY
Background
Some of the most important questions relating to the use of biological ther-
apy in inﬂammatory bowel diseases concern the duration of maintenance
therapy.
Aim
To assess the disease course and frequency of relapse of Crohn’s disease
(CD) following discontinuation of biological therapy, and to determine pre-
dictive factors for relapse.
Methods
One hundred twenty-one CD patients who had achieved clinical remission
following 1 year of biological therapy and for whom biological therapy was
then discontinued participated in this prospective observational study.
Eighty-seven CD patients had received inﬂiximab and 34 adalimumab. The
deﬁnition of relapse was an increase of >100 points in CDAI to at least a
CDAI of 150 points.
Results
Biological therapy was restarted within 1 year of treatment cessation in
45% of patients. Logistic regression analysis revealed that previous biologi-
cal therapy (P = 0.011) and dose intensiﬁcation during the 1-year course of
biological therapy (P = 0.024) were associated with the need for and the
time to the restarting of biological therapy. Smoking was observed to have
an effect that was not statistically signiﬁcant (P = 0.053).
Conclusions
Biological therapy was restarted a median of 6 months after discontinuation
in almost half of Crohn’s disease patients in who had been in clinical
remission following 1 year of biological therapy. These results suggest that,
in the event of the presence of certain predictive factors, biological therapy
should probably be continued for more than 1 year by most patients.
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INTRODUCTION
Antitumour necrosis factor (TNF) therapy (inﬂiximab or
adalimumab) has proven effective in the treatment of
Crohn’s disease (CD) and ulcerative colitis, both in trials
and in clinical practice.1–3 Some of the most important
questions relating to the use of biologicals include when
therapy should be stopped and whether these drugs are
still effective if they must be restarted in the event of a
clinical relapse.
Data suggest that similar to other lifelong diseases,
inﬂammatory bowel diseases (IBD) should be treated
continuously. However, the clinical beneﬁt of mainte-
nance therapy in symptom-free periods is less well
established. The World Congress of Gastroenterology’s
(WCOG) statement4 indicates that withdrawal of ther-
apy is possible in patients with CD who exhibit both
complete mucosal healing and no biological evidence of
inﬂammation [Evidence Level (EL): 2b]. For each
patient, disease history and response to therapy should
be taken into consideration. Data are currently available
from the STORI study5 and some single-centre studies
concerning the risk factors of disease recurrence after
discontinuation of successful biological therapy in CD.
In the STORI study, inﬂiximab therapy was terminated
in 115 patients in clinical remission after treatment
with combined scheduled inﬂiximab and a stable dose
of immunosuppressant for at least 1 year. Forty-ﬁve
per cent of patients relapsed following withdrawal of
inﬂiximab. Factors predicting time-to-relapse included:
male gender, previous steroid treatment, haemoglobin
level, elevated white blood cell count, higher-than-nor-
mal levels of C-reactive protein (CRP) or faecal calpro-
tectin, and the observation of mucosal lesions on
endoscopy.
The Hungarian National Health Insurance Fund
Administration reimbursement regulations specify that
biological therapy must be discontinued after a 1-year
treatment period in patients with luminal CD who have
achieved remission.
The identiﬁcation of factors predictive of the need
to restart biological therapy, including demographic-,
clinical-, laboratory- and treatment-related variables,
would be helpful when determining the optimum
duration of therapy. The aims of the present
study were therefore to assess the disease course and
the frequency of relapse in the year following man-
dated discontinuation of inﬂiximab or adalimumab
administration in CD patients who had achieved
clinical remission, and to determine possible predict-
ing factors.
PATIENTS AND METHODS
Study design and patients
The study, Relapse After Stopping biologicals in Hungary
(RASH), was a prospective observational study conducted
at ﬁve Hungarian tertiary referral centres, and was
approved by the Semmelweis University Regional and
Institutional Committee of Science and Research Ethics.
Analysis focused on patients who attained a state of clini-
cal remission (assessed via the Crohn’s Disease Activity
Index [CDAI]) after a 1-year period of biological therapy
at which time biological therapy was discontinued. One
hundred twenty-one consecutive CD patients were fol-
lowed. After responding to induction therapy, all patients
received maintenance inﬂiximab or adalimumab therapy
for 1 year, in accordance with Hungarian regulations,
and achieved a CDAI of  150 points by the end of the
1-year treatment period. Each centre followed patients
closely both during and after biological therapy, in accor-
dance with national guidelines (see details below).
Diagnosis was based on the Lennard-Jones criteria,6
while CD phenotype was determined in accordance with
the Montreal Classiﬁcation.7 The clinical characteristics
of these patients are presented in Table 1. In cases of
perianal CD, only patients with luminal disease activity,
but an inactive perianal ﬁstula were enrolled in the
study. Data on patients with active perianal disease
(either initially, or during the study period) were not
included in the analysis. Data relating to patients’ smok-
ing habits, previous appendectomy, perianal involvement,
the presence of extraintestinal manifestation (EIM), mag-
netic resonance imaging (MRI) or endoscopic ultrasound
(EUS) procedures, concomitant medication and previous
surgical procedures (resections, perianal procedures, or
colectomy) were collected from each centre.
Types of biological therapy and concomitant
immunosuppression
Eighty-seven CD patients received inﬂiximab and 34
adalimumab. Ninety-six patients (79%) were naive to
biological therapy. Eleven inﬂiximab- and 14 ada-
limumab-treated patients had received biological ther-
apy previously; that is, they were treated with a
biological agent before the 1-year period of biological
therapy analysed in the present study. It should be
reiterated that in Hungary biological therapy must be
discontinued after a 1-year treatment period in patients
with luminal disease who have achieved remission,
but can be restarted upon relapse, regardless of the
time between discontinuation and relapse. Previous
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switching to adalimumab was due to the loss of
response or intolerance to inﬂiximab. In cases involv-
ing inﬂiximab retreatment, only episodic inﬂiximab
had been administered previously. Concomitant immu-
nosuppression during induction was achieved with ste-
roids in 59.5% and with thiopurines in 85.1% of the
patients. Of the steroid-treated patients, 33% demon-
strated steroid dependence.
Assessment of response to biological therapy and
follow-up after treatment discontinuation
Clinical activity scores, determined by CDAI,8 were doc-
umented before the start of biological therapy, after 2, 6
and 12 weeks of therapy, every 2 months thereafter, at
the end of the year, and when resumption of biological
therapy was needed. The initial response to treatment
was assessed 12 weeks after therapy commenced. A clini-
cal response was deﬁned as a decrease of >70 points in
CDAI. Clinical remission was deﬁned as a CDAI  150
points. Patients who responded or achieved remission by
week 12 were offered a 1-year course of maintenance
therapy, after which the biological therapy was discontin-
ued. The deﬁnition of a relapse and an indication for
restarting biologicals was an increase of >100 points in
CDAI together with a CDAI of >150 points. Among
patients with perianal CD, relapses were due to luminal
Table 1 | Clinical characteristics of enrolled patients
Characteristics CD patients (n = 121)
Retreated CD
patients (n = 55)
Not retreated CD
patients (n = 66)
Gender (female/male) 64/57 23/32 41/25
Mean age at diagnosis (years) 25.4 (8–67) 24.1 (10–51) 26.4 (8–67)
Mean age at the beginning of biological therapy (years) 30.7 (17–63) 30 (17–63) 31.3 (18–60)
Montreal classiﬁcation
Age at diagnosis
<16 years (A1) 18 (14.9%) 10 (18.2%) 8 (12.1%)
17–40 years (A2) 89 (73.6%) 41 (74.5%) 48 (72.7%)
>40 years (A3) 14 (11.5%) 4 (7.3%) 10 (15.2%)
Location
Ileal (L1) 8 (6.6%) 2 (3.6%) 6 (9.1%)
Colonic (L2) 46 (38%) 21 (38.2%) 25 (37.9%)
Ileocolonic (L3) 66 (54.5%) 32 (58.2%) 34 (51.5%)
Upper GI (L4) 1 (0.9%) 0 1 (1.5%)
Behaviour
Inﬂammatory (B1) 46 (38%) 22 (40%) 24 (36.4%)
Stricturing (B2) 17 (14%) 7 (12.7%) 10 (15.2%)
Penetrating (B3)* 58 (48%) 26 (47.3%) 32 (48.5%)
Extraintestinal manifestation 70 (57.9%) 34 (61.8%) 36 (54.5%)
Concomitant medications
Corticosteroids 72 (59.5%) 39 (70.9%) 33 (50%)
Thiopurines 103 (85.1%) 46 (83.6%) 57 (86.4%)
Surgery before the biological therapy 54 (44.6%) 23 (41.8%) 31 (47%)
Previous biological therapy† 25 (20.7%) 15 (27.3%) 10 (15.2%)
Median CDAI at the start of biological therapy 340 307 300
Median CRP level at the start of biological therapy 9.8 12.5 7.9
Current smokers (%) 33 (30.3%)‡ 22 (40.7%)¶ 11 (20%)††
Appendectomy (%) 16 (22.2%)§ 5 (10.9%)** 11 (22.9%)‡‡
* Perianal ﬁstula in the patient’s history.
† Previous refers to treatment with biological agent before the 1-year period of biological therapy analysed in the study.
‡ Data of 12 patients were missing.
§ Data of 57 patients were missing.
¶ Data of 1 patients were missing.
** Data of 9 patients were missing.
†† Data of 11 patients were missing.
‡‡ Data of 48 patients were missing.
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disease in every case. Mucosal healing was deﬁned as the
absence of mucosal lesions and no signs of active inﬂam-
mation. Health authority regulations require mandatory
follow-up appointments at least every 3 months. These
visits involve a clinical assessment, a review of patient
diaries, CDAI determination, a laboratory assessment
(including CRP), and, every 6 months, a chest x-ray.
CRP level was regarded as elevated if it exceeded 10 mg/
dL. Speciﬁc details relating to patient selection and fol-
low-up were standardised and uniform in all participat-
ing specialised centres. All participating centres were
monitored for quality of care and compliance with regu-
lations by the Hungarian National Health Insurance
Fund Administration in June 2011.
End points
Data collection and analysis were performed at the 1st
Department of Medicine at the University of Szeged and
the 1st Department of Medicine Semmelweis University.
The primary end points were time to clinical relapse
after discontinuation of inﬂiximab or adalimumab, and
the identiﬁcation of factors associated with the risk of a
relapse. The secondary end points were the safety and
efﬁcacy of retreatment with biologicals in patients who
relapsed. Colonoscopy was offered to all of the patients
at the end of the therapy.
Statistical analysis
Variables were tested for normality with Shapiro Wilk’s
W test. The Chi-squared test and Chi-squared test with
Yates correction and logistic regression analysis were used
to assess the association between categorical clinical vari-
ables and the clinical or endoscopic outcome. Kaplan–
Meier survival curves were plotted for analysis with the
Log-Rank and Breslow tests. In addition, Cox-regression
analysis was utilised to assess the association between cat-
egorical clinical variables (gender, smoking, steroid ther-
apy, previous use of biological therapy, and CRP level at
52 weeks) and the probability of a clinical relapse leading
to the resumption of biologicals. Variables with P < 0.1
were included in the multivariate testing. A P value <0.05
was considered signiﬁcant. For statistical analysis, SPSS
version 15.0 (IBM, Chicago, IL, USA) was used.
RESULTS
Clinical efﬁcacy after weeks 12 and 52 of the 1-year
course of biological therapy
The median CDAI at the start of induction therapy was
340 (IQR: 320-354) while the median CRP level was
9.8 mg/L (IQR: 5–27.2). Of the patients enrolled, 2.7%
achieved remission at week 2, and 47.3% at week 6. Of
patients that initially responded to induction, 70.6%
achieved clinical remission at week 12, with a median
CDAI of 119 and a median CRP level of 4.3 mg/L. At
week 52, the median CDAI was 100 (IQR: 50–149),
while the median CRP level was 2.2 mg/L (IQR: 1–5.75).
Seventy-two patients had received steroids at the begin-
ning of the 1-year course of biological therapy. Corticos-
teroids were discontinued in 82% of patients after a
median of 8 weeks (IQR: 6–12). Of patients on thiopu-
rines (n = 103), 8.8% had stopped the immunomodula-
tors a median of 18 weeks (IQR: 14–25) after initiation
of biological therapy. The main reasons for withdrawing
thiopurines were the potential for infectious side-effects
in cases of combined immunosuppression with biologi-
cals, medication cost or intolerance to the drug. Patients
at a high risk of relapse continued to be treated with
combined therapy. Forty-three patients agreed to colo-
noscopy when biological therapy was discontinued, and
mucosal healing was demonstrated in 35% of these
patients. Dose intensiﬁcation of the biological drug was
needed in 10.4% of patients after a median period of
6 months (IQR: 4–8.25).
Predictors of need to restart of biological therapy
Within 1 year of discontinuation of biological therapy,
resumption of therapy was necessary in 45% of patients
who had achieved remission, with a median time to
resumption of 6 months (IQR: 3.75–12 months). In each
case, retreatment was necessitated by a clinical relapse.
The clinical characteristics of patients who restarted bio-
logical therapy are presented in Table 1. The median
CDAI at the time of resumption of biological therapy
was 307 (IQR: 253–359) while the median CRP level was
12.5 (IQR: 7–32.6) mg/L. Clinical remission was again
achieved in 54.7% of those who restarted biological ther-
apy, whereas 9.1% of the patients underwent surgery.
During further follow-up, 43% of the remaining patients
needed retreatment within 18–24 months.
In univariate analysis, smoking (P = 0.027, OR: 2.34,
95% CI: 1.09–5.01), the use of corticosteroids at the start
of the biological therapy (P = 0.005, OR: 3.43, 95% CI:
1.4–8.4), previous biological therapy (P = 0.013, OR:
3.05, 95% CI: 1.23–7.52), an elevated CRP level at the
start of the biological therapy (P = 0.025, OR: 2.44, 95%
CI: 1.11–5.36) and a dose intensiﬁcation during the 1-
year course of biological therapy (P = 0.001, OR: 15.4,
95% CI: 1.83–129.9) all proved to be associated with the
need to restart biological therapy. Variables without a
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signiﬁcant association are detailed in Table 2. Gender
and CRP levels were included in the multivariate analysis
(Table 2). No differences were shown regarding the type
on anti-TNF therapy.
In a logistic regression analysis, previous biological
therapy (P = 0.011, OR: 4.23, 95% CI: 1.39–12.84), and
dose intensiﬁcation (P = 0.024, OR: 12.96, 95% CI: 1.39–
120.5) were associated with the need to restart biological
therapy in these CD patients. Smoking had a noticeable
effect that failed, however, to meet statistical signiﬁcance
(P = 0.053). Steroid use (P = 0.06, OR: 1.67, 95% CI:
0.97–2.83) and elevated CRP (P = 0.08, OR: 2.38, 95%
CI: 0.92–6.19) at the start of the 1-year biological ther-
apy, and also female gender (P = 0.15, OR: 0.49, 95% CI:
0.19–1.28) also appeared to have an effect that was, how-
ever, not statistically signiﬁcant. Predictive factors of
restarting biological therapy in CD are listed in Table 3.
Analyses were also performed (n = 108) after exclusion
of steroid-dependent patients (n = 13) to assess the pre-
dictive factors for patients in remission not receiving ste-
roids. This, however, changed the outcome only slightly:
the effects of smoking, previous biological therapy, dose
intensiﬁcation and steroid use at the start of the 1-year
course of biological therapy were signiﬁcant. Moreover,
the CRP level at the start of therapy appeared to have a
potential role as predictive factor, although in this study
the association was not statistically signiﬁcant.
In a subsequent sensitivity analysis, patients who had
undergone dose intensiﬁcation were excluded. In this
multivariable logistic regression analysis, previous biolog-
ical therapy (P = 0.035, OR: 3.50, 95% CI: 1.10–11.1)
and male gender (P = 0.038, OR: 2.92, 95% CI: 1.06–8.2)
were identiﬁed as independent predictors of a need to
restart biologicals. It was noteworthy that among anti-
TNF-naive patients (96/121, 79%) the need for dose
intensiﬁcation (OR: 15.8) during the 1-year period of
biological therapy was the only independent predictor of
the need to restart biologicals. However, the analysis of
this subgroup was underpowered to detect differences,
with an OR ranging from 1.5–4.
In a Kaplan–Meier analysis with the Log-Rank and
Breslow tests, smoking, concomitant steroids, previous
biological therapy, elevated CRP level at week 52 when
biological therapy was discontinued, and dose intensiﬁca-
tion were signiﬁcantly associated with the time to the
restarting of biological therapy (Figure 1). In a subse-
quent Cox-regression analysis, previous biological ther-
apy (P = 0.001, HR: 2.77, 95% CI: 1.53–5.0) and elevated
CRP level at week 52 (P = 0.005, HR: 2.44, 95% CI:
1.31–4.54) were independently associated with the time
to reinitiation of inﬂiximab therapy, with smoking being
borderline-signiﬁcant.
Disease location and behaviour, the presence of the
perianal disease, the occurrence of extraintestinal mani-
festations, and previous surgery were not associated with
the reinitiation of biological therapy. No correlation was
found between mucosal healing and the frequency of,
nor time to, clinical relapse.
Table 2 | Univariate regression analysis of need for
retreatment with biologicals (signiﬁcant and
insigniﬁcant variables)
Factor P-value OR 95% CI
Dose intensiﬁcation during 1-year
biological therapy
0.001 15.4 1.83–129.9
Corticosteroids at start of
biological therapy
0.005 3.43 1.4–8.4
Previous biological therapy 0.013 3.05 1.23–7.52
Elevated CRP at start of
1-year biological therapy
0.025 2.44 1.11–5.36
Smoking 0.027 2.34 1.09–5.01
Elevated CRP at week 52* 0.37 1.69 0.53–5.4
Steroid dependency 0.31 1.67 0.62–4.48
Elevated CRP at week 12* 0.27 1.63 0.68–3.91
Remission at week 12 0.39 1.44 0.62–3.31
Appendectomy 0.6 1.34 0.45–4.03
Refractory to steroid therapy 0.53 1.32 0.56–3.11
Short disease duration 0.5 1.23 0.61–2.74
Type of TNF blocker 0.88 0.94 0.39–2.25
Extraintestinal manifestation 0.80 0.91 0.43–1.94
Concomitant thiopurine therapy 0.81 0.88 0.32–2.45
Previous surgery 0.60 0.82 0.38–1.75
Perianal manifestation 0.50 0.77 0.36–1.64
Male gender* 0.12 0.55 0.26–1.16
Behaviour 0.75 – –
Location 0.67 – –
*Included in the multivariate analysis.
Table 3 | Multivariate logistic regression: predictive
factors for restarting biological therapy in Crohn’s
disease
Factor P-value OR 95% CI
Dose intensiﬁcation 0.024 12.96 1.39–120.5
Previous biological therapy 0.011 4.23 1.39–12.84
Smoking 0.053 2.74 0.99–7.59
Elevated CRP at start of
1-year biological therapy
0.08 2.38 0.92–6.19
Corticosteroid use at start of
1-year biological therapy
0.06 1.67 0.97–2.83
Female gender 0.15 0.49 0.19–1.28
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Normal
Elevated
Previous biological therapy
(pLogRank = 0.004, pBreslow = 0.004)
Steroid therapy at the beginning of biological
therapy (pLogRank = 0.01, pBreslow = 0.012)
CRP at week 52-discontinuation of
biological therapy (pLogRank = 0.025,
pBreslow = 0.006)
Time after cessation of biological therapy (months)
Time after cessation of biological therapy (months) Time after cessation of biological therapy (months)
Does escalation during one-year biological
therapy (pLogRank<0.001, pBreslow<0.001)
Smoking at the beginning of biological
therapy (pLogRank = 0.013,
pBreslow = 0.011)
Yes
No
1.0
0.8
0.6
0.4
0.2
0.0
0.00 2.00 6.00 8.00 10.00 14.004.00 12.00
Figure 1 | In a Kaplan–Meier analysis with the Log-Rank and Breslow tests, smoking (pLogRank = 0.013,
pBreslow = 0.011), concomitant steroids (pLogRank = 0.01, pBreslow = 0.012), previous biological therapy
(pLogRank = 0.004, pBreslow = 0.004), an elevated CRP level at week 52, when the biological therapy was
discontinued (pLogRank = 0.025, pBreslow = 0.006), and dose intensiﬁcation (pLogRank < 0.001, pBreslow < 0.001)
were associated with the time to the restarting of biological therapy.
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Adverse events
Adverse events occurred in 10.9% of patients during the
1-year treatment period. None were serious and none led
to withdrawal of biological therapy. Steroid premedica-
tion was used in 51.2% of patients. Within the follow-up
period after reinitiation of biological therapy, 4% of
patients developed mild side-effects and 6% displayed an
infusion reaction.
DISCUSSION
A major ﬁnding of this prospective follow-up study is
that a high rate of clinical relapse exists within one year
of discontinuing of biological therapy in patients in clini-
cal remission. It was possible to identify clinically rele-
vant predictors of the need to restart biological therapy
due to clinical relapse. In univariate analysis, corticoste-
roid use at induction, smoking, previous biological ther-
apy, elevated CRP level at discontinuation of biological
therapy, and dose intensiﬁcation during the 1-year
course of biological therapy were associated with the
need for and time to the restarting of biological therapy.
Mucosal healing was not associated with the need for
biological therapy to be restarted. However, a clear limi-
tation of the present study is that the number of patients
assessed by colonoscopy was low, which prevents a ﬁrm
conclusion. To date, there are no established guidelines
as to whether and when biological therapy can be dis-
continued. Kamm et al. 9 proposed that biological ther-
apy should not be stopped in high-risk patients (those
who have undergone multiple previous operations, dem-
onstrated intolerance to multiple drugs or in whom the
disease is difﬁcult to control). Moreover, subgroups of
patients may remain in longstanding clinical remission.
In the longitudinal cohort study by Waugh et al., 50% of
patients relapsed within 477 days, while 35% remained
in sustained clinical remission for nearly 7 years.10 A
recently published review11 indicates that the average
one- and ﬁve-year relapse rates after discontinuation of
inﬂiximab in CD in the studies reported to date were
45% and 75%. Thus, it is of the utmost clinical impor-
tance to identify factors predictive of relapse.
The only prospective clinical trial so far, STORI, iden-
tiﬁed male sex, the absence of previous surgical resec-
tion, steroid treatment in the previous 6-12 months, a
CDEIS score >0, leucocyte count >6.0x109/L, haemoglo-
bin  145 g/L, a CRP level  5.0 mg/L, and faecal cal-
protectin  300 lg/g as predictors of relapse after the
cessation of biological therapy in patients in steroid-free
clinical remission.5 In the present prospective follow-up
study, we examined the predictors of clinical relapse in
both inﬂiximab and adalimumab-treated CD patients.
Dose intensiﬁcation, previous biological therapy, smok-
ing and steroid therapy at the time of induction, CRP
>10 mg/L at the beginning and end of therapy were
identiﬁed as predictors of the need for the restarting of
biological therapy. A similar trend was observed as
regards male gender. Retreatment of patients with bio-
logicals was effective and well tolerated in 50% of
patients. The overall relapse rates after the discontinua-
tion of biological therapy proved to be similar in both
the STORI study and the present study; however, the
rates of success of the retreatment differed. Because
there were substantial differences in the patient pheno-
type and management, the studies are difﬁcult to com-
pare. The mean duration of inﬂiximab therapy was
more than 2 years in the STORI trial, whereas it was
1 year in the present study. Another important differ-
ence was that the patients in the STORI study had been
in corticosteroid-free remission for the 6 months prior
to inclusion, while in this study treatment was stopped
even if steroids could not be tapered off. In the STORI
study, eligible patients were those treated with either a
thiopurine or methotrexate, whereas in this study 85%
of patients received combined immunomodulatory ther-
apy. Lastly, in the present study data revealed that the
previous use of biological therapy before the 1-year
treatment period may predict the risk of relapse after
the termination of anti-TNF therapy, while in the
STORI study, the effects of previous biological therapy
were not examined.
C-reactive protein is one of the most frequently stud-
ied laboratory parameters when predicting disease course
in IBD. Schnitzler et al.12 reported in 2009 that CRP
normalised in 186 of 309 patients who responded to inf-
liximab, and dropped by more than 50% in 123 addi-
tional patients. In the present study, we used a different
cut-off for the CRP level (<10 mg/L) as suggested by
previous randomised clinical trials with adalimumab3
and certolizumab13, 14 and previous ﬁndings from this
research group.15, 16 A phase 2 study14 indicated greater
differences in response and remission rates between the
certolizumab and placebo groups with a baseline CRP
level >10 mg/L. Kiss et al.15 more recently reported that
a normal/normalised CRP level at week 12, but not the
baseline CRP level (>10 mg/L) was associated with a
medium-term clinical beneﬁt. The present study revealed
that an elevated CRP level at the start of biological ther-
apy and at week 52 was associated with need for, and
time to, reinitiating biological therapy. This group has
evaluated the predictive potential of CRP in a further
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follow-up study.16 The accuracy of CRP in identifying
patients with active disease during prospective follow-up
was good overall (AUC: 0.82). In addition, in Kaplan–
Meier and Cox-regression analyses, CRP was an inde-
pendent predictor of 3- (P = 0.007) or 12-month
(P = 0.001) clinical relapses for patients in remission
who had an elevated hsCRP at diagnosis. The cut-off
values for both the static comparison (separation of
active disease and clinical remission) and the prediction
of clinical relapses were calculated by ROC analysis and
the cut-off values identiﬁed were 10.7 and 10.1 mg/L
respectively.
The authors are aware of the limitations of this
study. Endoscopic activity was assessed in only a
minority of the patients, and therefore it was not possi-
ble to determine whether mucosal healing is a predictor
of sustained remission after discontinuation of biologi-
cal therapy. Previous data demonstrated that patients
who displayed complete mucosal healing remained in
sustained remission when therapy was continuous.17, 19
Drug trough levels, antibody status18 and faecal calpro-
tectin were not assessed. In contrast, one of the
strengths of the present study is that the study cohort
consisted of well-characterised CD patients representing
the nationwide clinical practice in Hungary, it employed
standardised patient selection and follow-up, as regu-
lated by the Hungarian National Health Insurance Fund
Administration, which monitored all participating cen-
tres for quality of care and compliance with regulations
as of June 2011.
In conclusion, biological therapy was restarted a med-
ian of 6 months after discontinuation of biological ther-
apy in almost 50% of CD patients who had achieved
clinical remission following a 1-year course of biological
therapy. Our ﬁndings indicated that previous biological
therapy, steroid use and high CRP level at the start of
the 1-year period of biological therapy, dose intensiﬁca-
tion and smoking may predict the need to restart biolog-
ical therapy in patients with CD. Although the optimal
duration of biological therapy is still to be determined,
these results suggest that, in the presence of the above
predictors, biological therapy should probably be contin-
ued for more than one year.
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